Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
National Comprehensive Cancer Network, Medical Devices Deals, 2012 to YTD 2018 10
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Immunomedics Enters into Research Agreement with Fred Hutchinson Cancer Research Center 13
Vir Biotechnology and Fred Hutchinson Cancer Research Center Enter into Research Agreement 14
Context Therapeutics Enters into Partnership with Cedars-Sinai Medical Center, Fred Hutchinson Cancer Research Center and Synergie Lyon Cancer 15
Juno Therapeutics and Fred Hutchinson Cancer Research Center Enter into Joint Venture 16
BeyondSpring Pharma Enters into Agreement with Fred Hutchinson Cancer Research Center 17
Peregrine Pharma Enters into Research Agreement with National Comprehensive Cancer Network 18
Bristol-Myers Squibb Enters into Research Agreement with NCCN 19
A1M Pharma Enters into Rresearch Agreement with Fred Hutchinson Cancer Research Centre 20
Fred Hutch, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute Form Joint Venture 21
Juno Therapeutics Enters into Research Agreement with FHCRC 22
Blaze Bioscience Enters Into Agreement With Fred Hutchinson Cancer Research Center For Optides Discovery Program 23
Fred Hutchinson Cancer Research Center Enters Into Agreement With GlaxoSmithKline To Develop Drugs For Muscular Dystrophy 24
National Comprehensive Cancer Enters Into Co-Development Agreement With AVEO Pharma And Astellas Pharma 25
Licensing Agreements 27
Juno Therapeutics Enters into Licensing Agreement with Fred Hutchinson Cancer 27
Mustang Bio Enters into Licensing Agreement with Fred Hutchinson Cancer Research Center 28
Fred Hutchinson Cancer Research Center Enters into Licensing Agreement with Trianni 29
Nohla Therapeutics Enters into Licensing agreement with Fred Hutchinson Cancer Research Center 30
Rocket Pharma Enters into Licensing Agreement with Fred Hutchinson Cancer Research Center 31
Juno Therapeutics Enters into Licensing Agreement with FHCRC 32
Actinium Pharma Enters Into Licensing Agreement With Fred Hutchinson Cancer Research Center For BC8 33
National Comprehensive Cancer Network – Key Competitors 35
National Comprehensive Cancer Network – Key Employees 36
National Comprehensive Cancer Network – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 39
Government and Public Interest 39
Sep 11, 2018: New Guidelines Provide Vital Information for Women Diagnosed with the Most Common Type of Gynecologic Cancer 39
Aug 09, 2018: NCCN publishes first-ever U.S. guidelines for rare cancers associated with pregnancy 40
Jul 23, 2018: New Study in JNCCN Calls for Continued Aggressive Treatment for Breast Cancer in Women Under 40 41
Apr 26, 2018: New Translations of NCCN Guidelines for Patients Advance Global Mission to Empower People with Cancer 42
Apr 18, 2018: New Study Shows Why Cancer Cost Planning Needs to Start Accounting for People Under 65 43
Apr 04, 2018: NCCN Helps Strengthen Cancer Research Pipeline by Awarding Grants to Five Young Investigators 44
Mar 29, 2018: National Comprehensive Cancer Network Honors Key Contributors to the Improvement of Global Cancer Care and Dedication to the NCCN Mission 45
Mar 13, 2018: Testicular Cancer Survivors Need Adequate Screening for Long Term Heart Disease Risks 46
Feb 27, 2018: New NCCN Guidelines Incorporate PCF-Funded Research on Cancer Risk Genes 47
Jan 31, 2018: NCCN Reaches New Records for Guidelines, Resources, and Programs 49
Jan 25, 2018: NCCN Imaging Appropriate Use Criteria Endorsed by Intermountain Healthcare and Will be Included in the Intermountain AUC for Lung Cancer 50
Jan 22, 2018: Myriad Applauds New Consensus Statement From International Expert Panel On Screening Recommendations for Hereditary Prostate Cancer 51
Dec 01, 2017: Advocates Reveal Cancer Survivorship Challenges and Resources during National Comprehensive Cancer Network’s Patient Advocacy Summit 52
Nov 29, 2017: National Comprehensive Cancer Network Introduces New Guidelines for Patients with a Form of Cancer Associated with HIV and AIDS 53
Nov 20, 2017: NCCN, in Collaboration with Pfizer, Awards Nine Grants for Quality Improvement in Breast Cancer Care 54
Sep 27, 2017: Study Finds “Standard Care” Treatments in Breast Cancer Clinical Trials Not Always Standard 55
Aug 11, 2017: New NCCN Patient Resources for Rectal Cancer Now Available 56
May 19, 2017: NCCN and Pfizer Address Quality Improvement in Breast Cancer through Clinical Pathways 57
Other Significant Developments 58
Sep 17, 2018: New Benchmarking Tool for Measuring Development and Organization of Integrated Practice Units Published in Journal of the National Comprehensive Cancer Network 58
Jun 21, 2018: New Study in JNCCN Raises Questions about Resource Availability at Hospitals on Weekends and Holidays 59
May 14, 2018: New Tool Helps People with Leukemia Better Understand Their Treatment Options 60
Apr 10, 2018: NCCN Provides New, Free Database to Assist in Cancer Research Collaborations 61
Mar 28, 2018: Nearly Two Thousand Cancer Experts Come Together to Discuss Ways to Improve Quality, Effectiveness, and Efficiency of Care 62
Appendix 63
Methodology 63
About GlobalData 63
Contact Us 63
Disclaimer 63
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Key Facts 2
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
National Comprehensive Cancer Network, Deals By Therapy Area, 2012 to YTD 2018 9
National Comprehensive Cancer Network, Medical Devices Deals, 2012 to YTD 2018 10
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Immunomedics Enters into Research Agreement with Fred Hutchinson Cancer Research Center 13
Vir Biotechnology and Fred Hutchinson Cancer Research Center Enter into Research Agreement 14
Context Therapeutics Enters into Partnership with Cedars-Sinai Medical Center, Fred Hutchinson Cancer Research Center and Synergie Lyon Cancer 15
Juno Therapeutics and Fred Hutchinson Cancer Research Center Enter into Joint Venture 16
BeyondSpring Pharma Enters into Agreement with Fred Hutchinson Cancer Research Center 17
Peregrine Pharma Enters into Research Agreement with National Comprehensive Cancer Network 18
Bristol-Myers Squibb Enters into Research Agreement with NCCN 19
A1M Pharma Enters into Rresearch Agreement with Fred Hutchinson Cancer Research Centre 20
Fred Hutch, Memorial Sloan-Kettering Cancer Center and Seattle Children's Research Institute Form Joint Venture 21
Juno Therapeutics Enters into Research Agreement with FHCRC 22
Blaze Bioscience Enters Into Agreement With Fred Hutchinson Cancer Research Center For Optides Discovery Program 23
Fred Hutchinson Cancer Research Center Enters Into Agreement With GlaxoSmithKline To Develop Drugs For Muscular Dystrophy 24
National Comprehensive Cancer Enters Into Co-Development Agreement With AVEO Pharma And Astellas Pharma 25
Juno Therapeutics Enters into Licensing Agreement with Fred Hutchinson Cancer 27
Mustang Bio Enters into Licensing Agreement with Fred Hutchinson Cancer Research Center 28
Fred Hutchinson Cancer Research Center Enters into Licensing Agreement with Trianni 29
Nohla Therapeutics Enters into Licensing agreement with Fred Hutchinson Cancer Research Center 30
Rocket Pharma Enters into Licensing Agreement with Fred Hutchinson Cancer Research Center 31
Juno Therapeutics Enters into Licensing Agreement with FHCRC 32
Actinium Pharma Enters Into Licensing Agreement With Fred Hutchinson Cancer Research Center For BC8 33
National Comprehensive Cancer Network, Key Competitors 35
National Comprehensive Cancer Network, Key Employees 36
National Comprehensive Cancer Network, Subsidiaries 38
List of Figures
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
National Comprehensive Cancer Network, Medical Devices Deals, 2012 to YTD 2018 10